Table 2.

Anti-HBs seropositivity rates, seroprotection rates, proportion of subjects with antibody concentrations .100 mIU/ml and GMCs (ATP cohort for immunogenicity)

		Anti-HBs .2 mIU/ml		Anti-HBs .10 mIU/ml		Anti-HBs .100 mIU/ml		Anti-HBs GMC (mIU/ml)
Time	N	%	95% CI	%	95% CI	%	95% CI	Value	95% CI
PRE	399	0	0.0, 0.9	0	0.0, 0.9	0	0.0, 0.9	1.0	1.0, 1.0
P1	399	94.7	92.1, 96.7	75.9	71.4, 80.1	20.3	16.5, 24.6	27.9	23.9, 32.7
P2	399	100	99.1, 100	100.0	99.1, 100	99.7	98.6, 100	4594.5	4174.4, 5056.9

PRE, blood sampling prior to vaccination (i.e., at Month 0); P1, blood sampling after the first vaccine dose (i.e., at Month 1); P2, blood sampling after the second vaccine dose (i.e., at Month 2). N, number of subjects with available results; %, percentage of subjects with anti-HBs antibody concentration within the specified range; 95% CI, 95% confidence interval; GMC, geometric mean antibody concentration.